Login to Your Account



Vaccine Vindication

Long-Awaited Provenge Data Send Dendreon Soaring 133%

By Trista Morrison


Wednesday, April 15, 2009
Dendreon Corp.'s much-anticipated confirmatory Phase III trial of prostate cancer vaccine Provenge (sipuleucel-T) met its primary endpoint of improving overall survival, potentially ending the drug's two-year regulatory roller coaster ride and paving the way for the first FDA approval of a therapeutic cancer vaccine. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription